Phase III Study of S-877503 in Adult Patients with Attention-deficit/Hyperactivity Disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223176

Enrollment

190

Registered

2016-04-21

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-deficit/hyperactivity disorder

Interventions

investigational material(s) Generic name etc : S-877503 INN of investigational material : guanfacine Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient meets the DSM-5 criteria for a primary diagnosis of ADHD currently and during his/her childhood, etc.

Exclusion criteria

Exclusion criteria: Patient has complications such as serious hepatic disorder, renal disorder, heart disease, lung disease, hematological disease, and metabolic disease. Patient has psychiatric disease such as schizophrenia spectrum disorder and bipolar disorder. Patient has personality disorder or intellectual capacity disorder. Patient is orthostatic hypotensive. Patient has persistent bradycardia. Patient has suicidal tendency. etc.

Design outcomes

Primary

Measure	Time frame
efficacy Change from baseline in the ADHD-RS IV with adult prompts (Japanese version) at Week 10	—

Secondary

Measure	Time frame
safety efficacy CAARS (Japanese version), etc.	—

Countries

Japan

Contacts

Public ContactContact for Clinical Trial Information

Takeda Pharmaceutical Company Limited

smb.Japanclinicalstudydisclosure@takeda.com+81-6-6204-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026